Foghorn Therapeutics Inc. Common Stock (FHTX)
Foghorn Therapeutics Inc. (FHTX) is a biotechnology company focused on developing novel cancer therapies by targeting the chromatin regulatory system. Leveraging its proprietary Foghorn Discovery Engine, the company aims to identify and develop innovative treatments for difficult-to-treat cancers and diseases related to gene regulation.
Company News
Foghorn Therapeutics, a clinical-stage biotechnology company, announced participation in upcoming healthcare conferences and provided an update on its Phase 1 dose escalation trial for FHD-909 targeting SMARCA4 mutated cancers.
Optimism is growing in the fight against cancer as researchers make progress, with recent breakthroughs and increased funding for cancer research. Several biotech and biopharma companies have made significant developments in oncology, including Oncolytics Biotech, Nurix Therapeutics, Incyte, Regeneron Pharmaceuticals, and Foghorn Therapeutics.
Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of -7.27% and 32.94%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Here are some of the most notable stock movers Monday.
Concerns about a tough financing environment weighed on clinical-stage biotech stocks this week.